ACM
CTNM

ADAR1 Capital Management’s Contineum Therapeutics CTNM Stock Holding History

ADAR1 Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.57M Buy
278,961
+2,300
+0.8% +$30.2K 0.21% 108
2026
Q1 		$3.61M Sell
276,661
-2,300
-0.8% -$30.9K 0.21% 96
2025
Q4 		$3.19M Buy
278,961
+201,000
+258% +$2.29M 0.23% 74
2025
Q3 		$916K Sell
77,961
-88,838
-53% -$716K 0.09% 104
2025
Q2 		$662K Sell
166,799
-1,966
-1% -$8.54K 0.1% 104
2025
Q1 		$1.18M Buy
168,765
+86,531
+105% +$787K 0.22% 76
2024
Q4 		$1.2M Buy
82,234
+73,267
+817% +$1.16M 0.24% 70
2024
Q3 		$172K Buy
+8,967
New +$172K 0.03% 166

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ADAR1 Capital Management's CTNM Position: Q2 2026 in Review

ADAR1 Capital Management increased its Contineum Therapeutics (CTNM) stake by 0.83% in Q2 2026, buying an estimated $30.2K and bringing the position to 278,961 shares worth $4.57M. The position accounts for 0.21% of the portfolio, ranked #108.

ADAR1 Capital Management first reported a position in CTNM in Q3 2024 and has held it in 8 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • ADAR1 Capital Management held 278,961 shares of Contineum Therapeutics worth $4.57M as of Q2 2026.
  • ADAR1 Capital Management bought 2,300 Contineum Therapeutics shares in Q2 2026, an estimated $30.2K.
  • Contineum Therapeutics made up 0.21% of ADAR1 Capital Management's portfolio in Q2 2026, its #108 holding.
  • ADAR1 Capital Management first reported a position in Contineum Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.